SciELO - Scientific Electronic Library Online

 
vol.82 número5Evaluación del perfil metabólico y prevalencia de enfermedad cardiovascular en los ex combatientes de la guerra de MalvinasLa ley de salud mental en Argentina índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Medicina (Buenos Aires)

versión impresa ISSN 0025-7680versión On-line ISSN 1669-9106

Resumen

FAINGOLD, María C. et al. Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®). Medicina (B. Aires) [online]. 2022, vol.82, n.5, pp.752-759. ISSN 0025-7680.

Fast acting aspart insulin is a faster-acting formulation of aspart insulin, having nicotinamide and L-arginine added to the molecule, in order to achieve a faster absorption through the subcutaneous cellular tissue. Pharmacokinetic and pharmacodynamic studies showed a left-shifted mean serum concentration-time profile compared to the conventional formulation. Its efficacy profile is highlighted in terms of early postprandial glycemic control. In addition, fast acting aspart insulin allows a more flexible treatment schedule, as it may be administrated at mealtime, immediately before or up to 20 minutes after; this schedule represents an advantage regarding quality of life in patients with diabetes treated with prandial insulin, especially in populations such as children, pregnant women or elderly subjects. The safety and tolerability profiles are comparable to conventional aspart insulin.

Palabras clave : Aspart insulin; Pharmacokinetics; Pharmacodynamics; Posprandial glycemia.

        · resumen en Español     · texto en Español     · Español ( pdf )